Drug Profile
IBIO 200
Alternative Names: Coronavirus Vaccine - iBio/Beijing CC Pharming; IBIO-200; SARS-CoV-2 virus like particle vaccine-iBioLatest Information Update: 28 Mar 2024
Price :
$50
*
At a glance
- Originator Beijing CC-Pharming; iBio Inc
- Developer Beijing CC-Pharming; iBio Inc; Texas A&M University
- Class COVID-19 vaccines; Synthetic vaccines; Viral vaccines; Virus-like particle vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical COVID 2019 infections
Most Recent Events
- 28 Mar 2024 No recent reports of development identified for research development in COVID-2019-infections(Prevention) in China (Injection)
- 09 Apr 2020 iBio signs a Memorandum of Understanding with the Infectious Disease Research Institute for IBIO 200
- 26 Mar 2020 Preclinical trials in COVID-2019 infections (Prevention) in USA (unspecified route)